FIRST-LINE THERAPY
Clinical trials for FIRST-LINE THERAPY explained in plain language.
Never miss a new study
Get alerted when new FIRST-LINE THERAPY trials appear
Sign up with your email to follow new studies for FIRST-LINE THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost remission in Tough-to-Treat leukemia
Disease control Recruiting nowThis study compares a new treatment (venetoclax plus the CACAG regimen) to the standard chemotherapy ("3+7") for adults aged 14-75 with newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if the new combination leads to more complete remiss…
Matched conditions: FIRST-LINE THERAPY
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 17, 2026 06:43 UTC
-
New drug cocktail shows promise for tough stomach cancer
Disease control Recruiting nowThis study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal i…
Matched conditions: FIRST-LINE THERAPY
Phase: PHASE1, PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 06:38 UTC
-
New triple-drug attack targets hard-to-treat stomach cancer
Disease control Recruiting nowThis study tests a new three-drug combination for people with advanced stomach or esophageal cancer that has spread and has specific markers (HER2 and PD-L1). About 80 participants will receive zanidatamab, pembrolizumab, and chemotherapy. The goal is to see if this combination c…
Matched conditions: FIRST-LINE THERAPY
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 07, 2026 18:42 UTC